Related Experiment Videos
Childhood medulloblastoma: progress and future challenges
1Department of Neurology, Children's National Medical Centre, Washington, DC 20010, USA.
Abstract:
Medulloblastoma and other primitive neuroectodermal tumors are the most common malignant tumors of childhood. Progress has been slowly made in the management of such tumors. Long-term neurocognitive sequelae of treatment in children with medulloblastoma are common and recent treatment trials have attempted to reduce the amount of craniospinal radiation therapy or delay radiation therapy in attempts to reduce such sequelae. Surgery remains a critical component of treatment, although there is increasing concern about surgically-related complications, including the cerebellar mutism syndrome. For older children, craniospinal radiation remains an integral part of management. However, recent studies have suggested an excellent outcome after reduced-dose craniospinal radiation therapy and adjuvant chemotherapy. The role of chemotherapy is expanding for children with medulloblastoma and is now presently a component of protocols for children with average-risk and poor-risk disease. For children with poor-risk disease, intensifications of chemotherapy both during and after radiation therapy are presently being explored. Treatment of infants and young children with medulloblastoma remains problematic and a variety of different approaches are being investigated with the aims of both improving outcome and reducing long-term sequelae.
Insights
Childhood medulloblastoma treatment is evolving, balancing efficacy with reduced long-term side effects. Research focuses on optimizing radiation and chemotherapy to improve outcomes and minimize neurocognitive sequelae in pediatric patients.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Treatment Research
Background:
- Medulloblastoma and primitive neuroectodermal tumors are leading pediatric malignancies.
- Current treatments face challenges with long-term neurocognitive side effects and surgical complications like cerebellar mutism syndrome.
Purpose of the Study:
- To review current management strategies for medulloblastoma in children.
- To explore advancements in reducing treatment-related sequelae, particularly neurocognitive deficits.
- To highlight the evolving role of chemotherapy and radiation therapy modifications.
Main Methods:
- Review of recent treatment trials and studies on medulloblastoma management.
- Analysis of approaches aimed at reducing craniospinal radiation therapy doses or delaying its use.
- Evaluation of the expanding role and intensification of chemotherapy protocols.
Main Results:
- Reduced-dose craniospinal radiation with adjuvant chemotherapy shows promising outcomes in older children.
- Chemotherapy is increasingly integral for average-risk and poor-risk medulloblastoma.
- Novel approaches are being investigated for infants and young children to improve outcomes and reduce sequelae.
Conclusions:
- Treatment strategies for medulloblastoma are adapting to minimize long-term neurocognitive deficits in children.
- Optimized radiation and chemotherapy regimens are key to improving outcomes.
- Further research is critical for improving the treatment of medulloblastoma in infants and young children.